Filters

Search for: [Abstract = "16% men\).In the studied group 85,4% of patients received radioiodine for the first time, 6,1% of the patients had first episode of hyperthyroidism treated with radioiodine, 48,1% of the patients received radioiodine due to the first recurrence of the disease, 45,8% of the patients were given radioiodine for the second or the following recurrence of the disease. Patients received radioiodine activities ranged in three activity brackets\: up to 555 MBq 131\-I, 555\-800 MBq 131\-I and above 800 MBq 131\-I. Clinical status of the patient, intended treatment goals, US assessed thyroid volume and thyroid iodine uptake were all taken into account during radioiodine activity adjustment. 131\-I treatment efficacy was analyzed in the following patients’ subgroups in relation to sex, presence or absence of thyroid nodules, 131\-I activity used and in patients with Graves’ orbitopathy \(GO\). 72% of the patients remained permanently euthyroid or hypothyroid requiring L\-thyroxine supplementation 6 months after 131\-I administration which was defined as successful treatment in the studied group of the patients. 73% of the women and 66,7% of the men achieved desired therapeutic goal, while subgroups analysis in relation to applied 131\-I activity revealed that 76% of the patients who received lowest 131\-I activity \(<555 MBq\) and 68,5% of those who received medium 131\-I activity \(555\-800 MBq\) were consi"]

Number of results: 1

items per page

This page uses 'cookies'. More information